




**Tunable Extended-Release Capsules (TERC®)
for intravitreal injection of biologic molecules
prepared via electrospinning**


Katelyn Swindle-Reilly, PhD, CTO

CRS Innovation Showcase, July 24, 2023

Age-related Macular Degeneration: A Leading Cause of Blindness




**> 3 million US patients,
doubling by 2050¹**



**Treatment requires eye
injections as often as
every month**

Injection Burden is #1 Unmet Need


- ◎ Huge burden on patients and caregivers²
- ◎ Patients cannot maintain a frequent fixed treatment regime
- ◎ Wet AMD patients are being undertreated
- ◎ Vision is lost unnecessarily




Tunable Extended-Release Capsule: TERC™

Unique, patent-pending technology


Injectable in-office via small gauge needle	Adjustable porosity allows tuning of release kinetics	9-month release of active bevacizumab demonstrated <i>in vitro</i> ³
---	---	---



TERC™ shown to scale



Outer surface pores




TERC™ release kinetics³

Goal: Reduce injections to *two per year* or fewer

Sustained Therapeutic Release


Increasing HEPES salt results in more pores in outer layer
□ faster release



Long-term anti-VEGF release
>6 months

Uniform release after 1 month

Bioactivity maintained >9 months *in vitro*





Thank You
www.vitranu.com

Gordon Bethwaite, CEO
gbethwaite@vitranu.com

Katelyn Swindle-Reilly, PhD, CTO
kswindle-reilly@vitranu.com

See our talk
“Ocular Tolerability of Tunable
Extended Release Capsule (TERC)”
Tech Session 3: Ocular Delivery
Thursday 11-1, Champagne 3 & 4